Name: Recombinant Human Anti-NkG2A x Mouse Anti-GPC3 Bispecific Antibody (scFv-Fc)
SKU: KN-0725-N54
Rating: 5 (1 reviews)

Recombinant Human Anti-NkG2A x Mouse Anti-GPC3 Bispecific Antibody (scFv-Fc) is formed by fusing two different scFv fragments to the hinge and Fc regions, in which the Fc region are engineered by KIH. Two of scFv moiety has the antibody variable domain of either anti-NkG2A specificity or anti-GPC3 specificity, which produces bivalent IgG-like molecules with desired characteristics of intact antibodies. This BsAb can retarget NK cells to tumor cells. It is designed for the research of Hepatocellular cancer (HCC); Melanoma therapy.

Datasheet INQUIRY

Specifications

Targets

NkG2A & GPC3

Type

scFv-Fc

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Hepatocellular cancer (HCC); Melanoma

Host Animal 1

Human

Host Animal 2

Mouse

Targets

Target 1

NkG2A

Gene ID

3821

UniProt ID

P26715

Alternative Names

Killer cell lectin-like receptor subfamily C member 1; KLRC1; CD159 antigen-like family member A; NKG2-A; NKG2-1; NK group 2 member A; KLR family member C1; NK cell inhibitory receptor for HLA-E; NKG2; NKG2A; CD159A; killer cell lectin like receptor C1; NKG2-A/NKG2-B type II integral membrane protein; CD159 antigen-like family member A; NK cell receptor A; NKG2-A/B-activating NK receptor; CD159a

Target 2

GPC3

Gene ID

2719

UniProt ID

P51654

Alternative Names

SGB; DGSX; MXR7; SDYS; SGBS; OCI-5; SGBS1; GTR2-2; GPC3; glypican 3

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-NkG2A x Mouse Anti-GPC3 Bispecific Antibody (scFv-Fc) (KN-0725-N54). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-NkG2A x Mouse Anti-GPC3 Bispecific Antibody (scFv-Fc) (CAT#: KN-0725-N54)

Specifications

Targets

Customer Reviews and Q&As